Treatment with low-dose IL2 in SLE has shown to be beneficial in restoring the complement factors as well as decreasing the autoantibodies implicated in the disease, while the same could not be said about RA patients being treated with low-dose IL2 therapy. Here, IL2 is linked to systemic lupus erythematosus.